Drug Monograph
Perindopril
perindopril erbumine · Brand: Aceon (US), Coversyl (international)
Pharmacokinetic Profile
Half-Life
0.8–1 h (perindopril); 3–10 h (perindoprilat)
Metabolism
Hepatic esterase (prodrug → perindoprilat)
Protein Binding
60% (perindopril); 10–20% (perindoprilat)
Bioavailability
~75% (perindopril); ~25% (perindoprilat)
Volume of Distribution
~0.2 L/kg (perindoprilat)
Clinical Information
Drug Class
ACE Inhibitor (prodrug)
Available Doses
2 mg, 4 mg, 8 mg tablets
Route
Oral
Renal Adjustment
Yes — CrCl <30: not recommended
Hepatic Adjustment
No specific adjustment
Pregnancy
Contraindicated (Boxed Warning)
Lactation
Caution — excretion unknown in humans
Schedule / Legal Status
Prescription only (not controlled)
Generic Available
Yes
Black Box Warning
Yes — Fetal Toxicity
Perindopril Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Essential hypertension | Adults | Monotherapy or combination (especially with thiazide diuretics) | FDA Approved |
| Stable coronary artery disease — reduction of CV mortality and nonfatal MI | Adults with documented CAD without clinical heart failure | Adjunctive to antiplatelet, antihypertensive, and lipid-lowering therapy | FDA Approved |
Perindopril is one of the few ACE inhibitors with a specific labelled indication for cardiovascular risk reduction in stable coronary artery disease. The EUROPA trial demonstrated a 20% relative risk reduction in the composite of CV death, nonfatal MI, and cardiac arrest over 4.2 years in patients already receiving optimal secondary prevention therapy (FDA PI; EUROPA, Lancet 2003). In hypertension, perindopril can be used as monotherapy or combined with thiazide diuretics; twice-daily dosing may offer marginally superior blood pressure control compared with once-daily dosing in some patients.
Off-Label Uses
Heart failure with reduced ejection fraction (HFrEF): ACE inhibitors are a cornerstone of heart failure management per AHA/ACC/HFSA guidelines. Perindopril is used in many countries for this indication, though not specifically FDA-labelled for it. Evidence quality: High (class effect).
Diabetic nephropathy / renoprotection: The ADVANCE trial demonstrated renal benefits with perindopril/indapamide in type 2 diabetes, including reduction in microalbuminuria progression and nephropathy. Evidence quality: Moderate.
Secondary stroke prevention: The PROGRESS trial showed that perindopril combined with indapamide reduced recurrent stroke risk. Perindopril monotherapy alone did not achieve significance. Evidence quality: Moderate (combination only).
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Uncomplicated hypertension — new treatment | 4 mg once daily | 4–8 mg/day | 16 mg/day | May split into 2 divided doses; titrate at 2–4 week intervals based on BP response BID dosing slightly more effective than QD in clinical trials |
| Hypertension — on concurrent diuretic | 2–4 mg once daily | 4–8 mg/day | 16 mg/day | Consider reducing or stopping diuretic 2–3 days before initiation to reduce first-dose hypotension risk If diuretic cannot be stopped, supervise for ≥2 h after first dose |
| Stable CAD — cardiovascular risk reduction (adults ≤70 years) | 4 mg once daily × 2 weeks | 8 mg once daily | 8 mg/day | Based on EUROPA protocol; add to existing antiplatelet, statin, and beta-blocker therapy NNT = 50 over 4 years for 1 major CV event prevented |
| Stable CAD — cardiovascular risk reduction (elderly >70 years) | 2 mg once daily × 1 week | 8 mg once daily | 8 mg/day | Stepped titration: 2 mg → 4 mg (week 2) → 8 mg (week 3+) if tolerated Monitor BP closely during each step-up |
Renal Impairment Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| CrCl >30 mL/min | 2 mg once daily | 2–8 mg/day | 8 mg/day | Perindoprilat clearance is reduced; titrate cautiously |
| CrCl <30 mL/min | Not recommended | Limited clinical data; consider alternative agent | ||
| Haemodialysis | 2 mg on dialysis days | Per clinical response | 8 mg/day | Perindopril is dialyzable (clearance 52 mL/min); dose post-dialysis or supplement as needed |
Elderly (Hypertension)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Elderly hypertension (≥65 years) | 4 mg/day in 1–2 divided doses | 4–8 mg/day | 8 mg/day (limited data above 8 mg) | Plasma levels approximately 2-fold higher in elderly (>70 y) due to increased conversion and decreased renal clearance Monitor closely if dose >8 mg is considered |
Clinical Pearl — Dosing Considerations
Perindopril can be taken with or without food, though food reduces perindoprilat bioavailability by approximately 35%. In clinical trials, it was generally given in a non-fasting state. The clinical impact of this food interaction is considered modest (~20% reduction in ACE inhibition), but for maximal consistency, advise patients to take it at the same time each day relative to meals. No hepatic dose adjustment is specifically required despite perindopril being a prodrug activated in the liver.
Pharmacology
Mechanism of Action
Perindopril is a non-sulfhydryl prodrug ACE inhibitor. Following oral administration, it undergoes hepatic ester hydrolysis to form its active diacid metabolite, perindoprilat, which competitively inhibits angiotensin-converting enzyme (ACE). By blocking the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, perindoprilat reduces systemic vascular resistance, decreases aldosterone secretion, and promotes natriuresis. Concurrently, ACE inhibition slows the degradation of bradykinin, a vasodilatory peptide, contributing to the antihypertensive effect and also mediating the characteristic dry cough seen with this drug class. At the 8 mg dose, ACE inhibition reaches 80–90% at peak, persisting for 10–12 hours, with approximately 60% inhibition remaining at 24 hours. Beyond blood pressure lowering, perindopril has demonstrated direct cardiovascular protective effects, including improvements in endothelial function, reduction of vascular remodelling, and anti-inflammatory activity within the arterial wall.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Tmax ~1 h (perindopril), 3–7 h (perindoprilat); bioavailability ~75% (parent); food reduces perindoprilat AUC by ~35% | Rapid absorption of parent compound; food effect is modest and clinically acceptable but may be relevant at lower doses |
| Distribution | Protein binding 60% (perindopril), 10–20% (perindoprilat); Vd ~0.2 L/kg; minimal CNS penetration (<5%) | Low protein binding of active metabolite means drug-drug interactions via displacement are unlikely; poor brain penetration limits CNS adverse effects |
| Metabolism | Hepatic esterase hydrolysis to perindoprilat (active); additional glucuronidation and dehydration to 5 inactive metabolites; not CYP-mediated | Non-CYP metabolism reduces risk of hepatic drug interactions; prodrug design ensures consistent activation in liver |
| Elimination | t½ 0.8–1 h (perindopril), 3–10 h effective (perindoprilat), terminal 30–120 h; renal excretion (4–12% unchanged); dialyzable | Terminal half-life reflects slow dissociation from tissue ACE; dose reduction needed in renal impairment; drug removed by haemodialysis |
Side Effects
Data from placebo-controlled U.S. trials (n=1,012 perindopril patients) and the EUROPA study (n=12,218). Overall adverse event frequency was similar between perindopril and placebo groups (~75% in each group for hypertension trials).
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Cough | 12.0% (vs 4.5% placebo) | Class effect mediated by bradykinin accumulation; dry, nonproductive; resolves on discontinuation; led to withdrawal in 1.3% of patients |
| Headache | 23.8% | Common across both treatment and placebo groups in trials; typically transient and self-limiting at treatment initiation |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness | 8.2% (vs 8.5% placebo) | Dose-related despite similar overall incidence to placebo; most pronounced in first days of therapy and with concomitant diuretics |
| Upper respiratory infection | 8.6% | Not clearly distinguished from placebo rates; managed symptomatically |
| Asthenia / Fatigue | 7.9% | Generally mild and often improves over first weeks of therapy; assess if persistent to rule out excessive blood pressure lowering |
| Back pain | 5.8% (vs 3.1% placebo) | Only adverse event besides cough with ≥2% excess over placebo |
| Rhinitis | 4.8% | May overlap with ACE inhibitor-related upper airway effects |
| Lower extremity pain | 4.7% | Musculoskeletal; monitor if concurrent statin therapy |
| Diarrhoea | 4.3% | Usually self-limiting; no dose adjustment typically needed |
| Peripheral oedema | 3.9% | Evaluate for underlying cardiac or renal cause if new-onset |
| Nausea | 2.3% | May improve if taken with food |
| Rash | 2.3% | If progressive or accompanied by eosinophilia, evaluate for drug hypersensitivity |
| Sleep disorder | 2.5% | May include insomnia; consider timing adjustment if disruptive |
| ALT elevation | 1.6% (vs 0.9% placebo) | Generally mild and transient; resolved after discontinuation in clinical trials |
Serious
Serious Adverse Effects (regardless of frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Angioedema (face, tongue, glottis, larynx) | 0.1% | Any time; often within first weeks | Discontinue immediately; administer epinephrine if airway compromise; never rechallenge; higher risk in Black patients |
| Symptomatic hypotension | 0.8% | First dose, especially with volume depletion | Volume resuscitation; hold dose; reassess diuretic therapy; titrate more slowly if restarting |
| Hyperkalemia | Uncommon (<1%) | Weeks to months, especially with renal impairment | Check potassium within 1–2 weeks of initiation; discontinue K-sparing diuretics and supplements; reduce or hold dose if K >5.5 mEq/L |
| Acute renal failure | Rare | Days to weeks, especially with renal artery stenosis | Discontinue; investigate bilateral renal artery stenosis; volume resuscitate; may require temporary dialysis support |
| Neutropenia / Agranulocytosis | 0.1% | Weeks to months; higher risk with collagen vascular disease or renal impairment | Monitor WBC periodically in at-risk patients; discontinue if neutrophils <1,000/mm³; counsel to report signs of infection promptly |
| Hepatic failure / Cholestatic jaundice | Very rare | Variable | Discontinue immediately if jaundice or significant transaminase elevation develops; ACE inhibitor-associated hepatotoxicity can progress to fulminant necrosis |
| Anaphylactoid reactions (including with dialysis membranes) | Very rare | During high-flux dialysis or LDL apheresis | Avoid ACE inhibitors with high-flux polyacrylonitrile membranes; use alternative dialyzer membrane or antihypertensive |
Discontinuation
Discontinuation Rates
Hypertension (U.S. Placebo-Controlled)
6.5% vs 6.7% placebo
Top reasons: Cough, headache, asthenia, dizziness
Stable CAD (EUROPA Trial)
~22% vs ~22% placebo
Top reasons: Cough (2.7%), drug intolerance (2.4%), hypotension (1.0%)
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Cough | 1.3–2.7% | Higher in EUROPA (longer duration); class effect; resolves within days to weeks of stopping |
| Drug intolerance (general) | 2.4% | EUROPA data; encompasses multiple non-specific complaints |
| Hypotension | 1.0% | EUROPA data; first-dose and volume-depletion related |
| Headache | ~1% | U.S. hypertension trials; generally transient |
Management of ACE Inhibitor Cough
Dry cough is the most clinically significant tolerability issue with perindopril, affecting approximately 12% of patients. If cough is bothersome and persistent beyond 4–8 weeks, consider switching to an angiotensin II receptor blocker (ARB), which provides similar RAAS blockade without significant bradykinin accumulation. Cough typically resolves within 1–4 days of discontinuation. Do not attribute chronic cough to the ACE inhibitor without first excluding other causes (post-nasal drip, asthma, GORD).
Drug Interactions
Perindopril is not metabolised via the cytochrome P450 system. Its primary interactions are pharmacodynamic, relating to potassium homeostasis, renal haemodynamics, and dual RAAS blockade. Protein binding of the active metabolite perindoprilat is low (10–20%), so displacement interactions are not clinically relevant.
Major
Sacubitril/Valsartan (Entresto)
MechanismNeprilysin inhibition combined with ACE inhibition causes excessive bradykinin accumulation
EffectMarkedly increased risk of angioedema
ManagementContraindicated; allow ≥36-hour washout between perindopril and sacubitril/valsartan
FDA PI
Major
Aliskiren (in diabetic patients)
MechanismDual RAAS blockade via direct renin inhibition + ACE inhibition
EffectIncreased risk of hyperkalemia, hypotension, and acute renal failure
ManagementContraindicated in patients with diabetes; avoid in all patients with GFR <60 mL/min
FDA PI
Major
Potassium-Sparing Diuretics / K+ Supplements
MechanismACE inhibitors reduce aldosterone, decreasing potassium excretion; additive hyperkalaemic effect
EffectPotentially life-threatening hyperkalemia
ManagementAvoid routine co-prescription of spironolactone, eplerenone, amiloride, or K+ supplements unless clearly indicated with close K+ monitoring
FDA PI
Moderate
NSAIDs (including COX-2 inhibitors)
MechanismNSAIDs reduce renal prostaglandin synthesis, opposing vasodilatory and natriuretic effects of ACE inhibitors
EffectAttenuated antihypertensive response; increased risk of renal impairment, especially in elderly or volume-depleted patients
ManagementMonitor BP and renal function; use lowest effective NSAID dose for shortest duration; consider paracetamol as alternative analgesic
FDA PI
Moderate
Lithium
MechanismACE inhibitors reduce lithium renal clearance by decreasing GFR and promoting proximal tubular reabsorption
EffectIncreased serum lithium levels with risk of toxicity
ManagementMonitor lithium levels frequently when initiating, adjusting, or discontinuing perindopril; dose-adjust lithium as needed
FDA PI
Moderate
Diuretics (Thiazide / Loop)
MechanismDiuretic-induced volume depletion enhances first-dose hypotensive response to ACE inhibition
EffectExcessive symptomatic hypotension, especially after the first dose of perindopril
ManagementConsider reducing or holding diuretic 2–3 days before starting perindopril; if not possible, monitor closely for ≥2 hours after first dose
FDA PI
Moderate
Injectable Gold (sodium aurothiomalate)
MechanismUnknown; possibly kinin-mediated vasodilation
EffectNitritoid reactions: facial flushing, nausea, vomiting, and hypotension
ManagementBe aware of this reaction in patients receiving both agents; consider alternative antirheumatic if recurrent
FDA PI
Moderate
mTOR Inhibitors (e.g., sirolimus, everolimus, temsirolimus)
MechanismmTOR inhibitors may inhibit bradykinin degradation; additive with ACE inhibitor effect
EffectIncreased risk of angioedema
ManagementMonitor for angioedema symptoms; consider ARB alternative if angioedema occurs
FDA PIMonitoring
-
Blood Pressure
Each visit; 2–4 weeks after dose changes
Routine Measure seated and standing BP at initiation to assess orthostatic component. Monitor closely for first-dose hypotension, especially in diuretic-treated or volume-depleted patients. Target per current hypertension guidelines. -
Serum Potassium
Baseline, 1–2 weeks after initiation, then periodically
Routine ACE inhibitors reduce aldosterone, decreasing potassium excretion. Higher risk of hyperkalemia with renal impairment, diabetes, concomitant K-sparing agents, or K+ supplements. Hold dose if K+ >5.5 mEq/L. -
Renal Function
Baseline, 1–2 weeks after initiation, then every 3–6 months
Routine Check serum creatinine and eGFR. A rise of up to 30% in creatinine from baseline is acceptable if stable. If creatinine rises >30% or eGFR falls significantly, evaluate for renal artery stenosis and consider dose reduction or discontinuation. -
Complete Blood Count
Periodically in high-risk patients
Trigger-based Monitor WBC periodically in patients with collagen vascular disease (e.g., SLE, scleroderma), renal impairment, or those receiving immunosuppressants. Neutropenia/agranulocytosis reported in 0.1%. -
Hepatic Function
If signs of hepatic injury develop
Trigger-based ALT elevations (1.6% vs 0.9% placebo) have been reported. Discontinue immediately if jaundice or significant transaminase rises occur, as rare progression to hepatic necrosis has been described with ACE inhibitors. -
Blood Glucose
First month in diabetic patients
Trigger-based ACE inhibitors may enhance insulin sensitivity. Monitor glycaemic control more closely during the first month in patients receiving oral hypoglycaemic agents or insulin; dose adjustments of antidiabetic therapy may be needed.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity: Known allergy to perindopril, any ACE inhibitor, or any excipient of the formulation.
- History of angioedema: Prior angioedema with an ACE inhibitor, or hereditary/idiopathic angioedema.
- Pregnancy: Contraindicated at any stage; direct fetal toxicity including oligohydramnios, renal failure, skull hypoplasia, and death (FDA Boxed Warning).
- Concomitant neprilysin inhibitor: Do not use within 36 hours of sacubitril/valsartan due to angioedema risk.
- Aliskiren co-administration in diabetes: Contraindicated dual RAAS blockade.
Relative Contraindications (Specialist Input Recommended)
- Bilateral renal artery stenosis or stenosis of a solitary kidney: High risk of acute renal failure from loss of angiotensin II-mediated efferent arteriolar tone. If used, requires very close renal function monitoring under nephrology or hypertension specialist guidance.
- Severe aortic or mitral stenosis / hypertrophic cardiomyopathy: Afterload reduction may precipitate haemodynamic compromise. Cardiologist co-management advised.
- Severe renal impairment (CrCl <30 mL/min): Not recommended by the FDA label; if considered for compelling indication, requires close electrolyte and renal monitoring by a nephrologist.
Use with Caution
- Volume or sodium depletion: Patients on diuretics, salt-restricted diets, or experiencing diarrhoea/vomiting are at elevated risk of first-dose hypotension.
- Collagen vascular disease (SLE, scleroderma): Increased risk of neutropenia/agranulocytosis; monitor WBC.
- Hepatic impairment: Perindopril is a prodrug requiring hepatic activation; though no formal dose adjustment is stated, severe hepatic disease may affect conversion to perindoprilat. Rare cases of cholestatic jaundice and hepatic failure have been reported with ACE inhibitors.
- Patients undergoing major surgery or anaesthesia: ACE inhibitors may potentiate hypotension with anaesthetic agents; some anaesthetists recommend withholding on the morning of surgery.
- High-flux dialysis membranes: Risk of anaphylactoid reactions with polyacrylonitrile (AN69) membranes. Use alternative membranes or antihypertensive class.
- Black patients: Higher incidence of angioedema with ACE inhibitors; may also have attenuated antihypertensive response as monotherapy.
FDA Boxed Warning
Fetal Toxicity
When pregnancy is detected, perindopril should be discontinued as soon as possible. Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus, including oligohydramnios, fetal renal failure, hypotension, skull hypoplasia, and neonatal death. Exposure during the second and third trimesters is most clearly associated with harm, but first-trimester exposure also warrants discontinuation and transition to a pregnancy-safe antihypertensive agent.
Patient Counselling
Purpose of Therapy
Perindopril works by relaxing blood vessels, lowering blood pressure, and protecting the heart and kidneys. Depending on the reason for prescribing, it may be used to treat high blood pressure, reduce the risk of heart attacks in patients with existing coronary artery disease, or protect kidney function. It does not cure these conditions but provides ongoing protection when taken regularly.
How to Take
Take perindopril once daily (or as directed by your prescriber), at the same time each day. It can be taken with or without food. Do not stop taking perindopril without discussing with your doctor, even if you feel well, as blood pressure control and cardiovascular protection require continuous treatment. If you miss a dose, take it as soon as you remember unless it is nearly time for your next dose — in that case, skip the missed dose and continue your regular schedule.
Dry Cough
Tell patient
A persistent, dry, tickly cough occurs in roughly 1 in 8 patients taking this medication. It is not dangerous but can be bothersome. It is caused by the way the drug works and is not a sign of lung disease. If the cough does not improve after several weeks, the prescriber can switch you to a similar medication that does not cause this side effect.
Call prescriber
If cough is persistent and interferes with sleep, daily activities, or quality of life; if accompanied by wheezing, breathlessness, or chest tightness (which may suggest a different diagnosis).
Dizziness & Lightheadedness
Tell patient
Feeling dizzy or lightheaded can occur, particularly when first starting the medication or after a dose increase. It is related to blood pressure lowering. Rise slowly from sitting or lying positions. Stay well hydrated, especially in hot weather or during illness with vomiting or diarrhoea.
Call prescriber
If dizziness causes fainting or near-fainting episodes; if it does not improve after the first week; or if accompanied by significant volume loss from vomiting or diarrhoea.
Swelling (Angioedema)
Tell patient
In rare cases, this medication can cause swelling of the face, lips, tongue, or throat. This is a serious allergic-type reaction that requires immediate medical attention. It can happen at any time during treatment, not only when first starting.
Call prescriber
Seek emergency medical care immediately if you notice swelling of the face, mouth, tongue, or throat, or if you have difficulty breathing or swallowing. Stop taking the medication and do not take any more until advised by a doctor.
Pregnancy & Contraception
Tell patient
This medication can cause serious harm or death to an unborn baby. Women of childbearing potential should use reliable contraception while taking perindopril. If you are planning pregnancy, your prescriber should switch you to a pregnancy-safe blood pressure medication before conception.
Call prescriber
Contact your prescriber immediately if you become pregnant or suspect pregnancy. Do not wait for your next appointment.
Potassium & Diet
Tell patient
This medication can raise potassium levels in the blood. Avoid using potassium-based salt substitutes (such as Lo-Salt) and do not take potassium supplements unless specifically instructed by your doctor.
Call prescriber
If you experience muscle weakness, irregular heartbeat, tingling, or numbness — these may indicate elevated potassium levels.
Signs of Infection
Tell patient
In very rare cases, this medication can lower white blood cell counts. Report any signs of infection, such as sore throat, fever, or mouth ulcers, promptly to your doctor so that a blood test can be done if needed.
Call prescriber
If you develop fever, sore throat, or other signs of infection, especially if you also have kidney disease or an autoimmune condition.
Sources
Regulatory (PI / SmPC)
- Perindopril erbumine tablets prescribing information (Aurobindo Pharma). DailyMed / NLM, revised March 2024. DailyMed Label Current FDA-approved prescribing information; primary source for dosing, contraindications, adverse reactions, and drug interactions.
- Aceon (perindopril erbumine) tablets prescribing information. FDA label, 2012 revision. FDA Label PDF Comprehensive FDA label including EUROPA trial data, detailed adverse event rates, and pharmacokinetic parameters referenced throughout this monograph.
Key Clinical Trials
- Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788. doi:10.1016/S0140-6736(03)14286-9 Landmark trial of 12,218 patients demonstrating 20% relative risk reduction in CV death, MI, and cardiac arrest with perindopril 8 mg/day in stable CAD.
- PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–1041. doi:10.1016/S0140-6736(01)06178-5 Demonstrated stroke recurrence reduction with perindopril/indapamide combination (but not perindopril monotherapy) in patients with cerebrovascular disease.
- Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840. doi:10.1016/S0140-6736(07)61303-8 Large RCT showing CV event reduction and renoprotective benefits with perindopril/indapamide in type 2 diabetes, regardless of baseline blood pressure.
- Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial—Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906. doi:10.1016/S0140-6736(05)67185-1 Showed superiority of amlodipine±perindopril over atenolol±bendroflumethiazide in hypertensive patients; stopped early for benefit.
Guidelines
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006 Comprehensive US hypertension guideline positioning ACE inhibitors as first-line agents for compelling indications including CAD, CKD, and diabetes.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145(18):e895–e1032. doi:10.1161/CIR.0000000000001063 Supports ACE inhibitors as foundational therapy in HFrEF; relevant to off-label use of perindopril in heart failure management.
Mechanistic / Basic Science
- Ferrari R. Perindopril and remodeling in elderly with acute myocardial infarction (PREAMI). Circulation. 2006;114(suppl II):II-437. Presented at AHA 2006. Demonstrated attenuation of left ventricular remodelling with perindopril 8 mg in elderly post-MI patients; mechanistic basis for cardioprotective effects.
- Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73(1):237–246. doi:10.1016/j.cardiores.2006.10.021 EUROPA substudy showing perindopril improved endothelial function and reduced oxidative stress markers, providing mechanistic insight into CV protection.
Pharmacokinetics / Special Populations
- Bussien JP, Waeber B, Nussberger J, et al. Once-daily treatment of mild to moderate hypertension with perindopril. J Hypertens. 1988;6(suppl 3):S17–S20. Early dose-response and PK study establishing the once-daily dosing profile and ACE inhibition kinetics of perindopril in hypertensive patients.
- Louis WJ, Conway EL, Drummer OH, et al. Perindopril pharmacokinetics in the elderly. Br J Clin Pharmacol. 1992;33(2):175–181. doi:10.1111/j.1365-2125.1992.tb04022.x Demonstrated approximately 2-fold higher perindoprilat levels in elderly patients (>70 years) due to increased conversion and reduced renal clearance.
- Speirs C, Wagstaff AJ. Perindopril: an updated review of its therapeutic use in hypertension. Drugs. 1995;49(3):440–466. doi:10.2165/00003495-199549030-00008 Comprehensive review of perindopril pharmacology, pharmacokinetics across populations, and clinical efficacy data from early clinical trials.